Search

Your search keyword '"Vsianska P"' showing total 2 results
Start Over Author "Vsianska P" Topic medicine
2 results on '"Vsianska P"'

1. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.

Author

Karthick Raja Muthu Raja, Lenka Kubiczkova, Lucie Rihova, Martin Piskacek, Pavla Vsianska, Renata Hezova, Ludek Pour, and Roman Hajek

Subjects
Medicine, Science
Abstract

BACKGROUND: Multiple myeloma (MM) is a plasma cell malignancy frequently associated with impaired immune cell numbers and functions. In MM, several studies have previously shown that CD4 regulatory T (Treg) cells hamper effector T cell functions and enhance immune dysfunction. In this study, we aimed to prove the presence of functionally suppressive Treg cells expressing CD8 phenotype (CD8 Treg cells) in MM. To the best of our knowledge, this has not been reported previously in MM. METHODS: We analyzed CD8 Treg cells and their transcription factor FoxP3 from 64 newly diagnosed MM patients using flow cytometry and real time-polymerase chain reaction (RT-PCR). RNA profile of cytokines in CD8 Treg cells was also assessed using RT-PCR. CD8 Treg cells from 5 MM patients and 5 healthy donors were functionally evaluated using proliferation assays. RESULTS: CD8 Treg cells (CD8+CD25hi+) were significantly elevated in MM patients (P

Published
2012
Full Text
View/download PDF

2. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Author

Claudia Brandt-Hagens, Stefania Oliva, Pavla Všianská, Maria Teresa Petrucci, Roman Hájek, Romana Jugooa, Monica Galli, Mattia D'Agostino, Rossella Ribolla, Davine Hofste op Bruinink, Pieter Sonneveld, Andrea Capra, Bronno van der Holt, Tania Villanova, Massimo Offidani, Michele Cavo, Lucia Pantani, Rossella Troia, Mario Boccadoro, Paola Omedè, Lucie Rihova, Milena Gilestro, Vincent H.J. van der Velden, Oliva S., Bruinink D.H., Rihova L., D'Agostino M., Pantani L., Capra A., van der Holt B., Troia R., Petrucci M.T., Villanova T., Vsianska P., Jugooa R., Brandt-Hagens C., Gilestro M., Offidani M., Ribolla R., Galli M., Hajek R., Gay F., Cavo M., Omede P., van der Velden V.H.J., Boccadoro M., Sonneveld P., Hematology, and Immunology

Subjects
Melphalan, Male, medicine.medical_specialty, Neoplasm, Residual, Population, Urology, Bone Marrow Cells, Article, Dexamethasone, Disease-Free Survival, Bortezomib, EuroFlow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Autograft, Humans, Medicine, Autografts, education, Lenalidomide, Multiple myeloma, RC254-282, education.field_of_study, Antineoplastic Combined Chemotherapy Protocol, medicine.diagnostic_test, business.industry, Hematopoietic Stem Cell Transplantation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Hematology, Translational research, Middle Aged, medicine.disease, Flow Cytometry, Minimal residual disease, body regions, Survival Rate, medicine.anatomical_structure, Risk factors, Oncology, Bone Marrow Cell, Female, Bone marrow, business, Multiple Myeloma, medicine.drug, Fluorescence in situ hybridization, Human
Abstract

Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed by bortezomib-lenalidomide-dexamethasone (VRd) versus no consolidation, and lenalidomide maintenance. Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based MFC protocols (eight colors, two tubes) with 10−4−10−5 sensitivity. At enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0.39; p p

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results